Appili Therapeutics Inc Class A (APLI) AI Stock Analysis

• Market Cap: $1.82M
• Dividend Yield: N/A
• Average Volume (3M): 28.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: -86.89%
• EPS Growth: 30.77%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 121,266,120
• 10 Day Avg. Volume: 13,255
• 30 Day Avg. Volume: 28,791
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 7.17
• Enterprise Value/Revenue: 129.88
• Enterprise Value/Gross Profit: 140.27
• Enterprise Value/Ebitda: 36.18
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Appili Therapeutics Inc Class A faces significant financial challenges, with persistent unprofitability and high leverage weighing heavily on its score. While technical indicators and valuation metrics are weak, recent corporate events show promise with potential funding and strategic partnerships. However, the termination of a key agreement adds uncertainty. Overall, the stock's outlook is cautious, with financial health being the most significant concern.

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company Description

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

How the Company Makes Money

Appili Therapeutics Inc generates revenue primarily through the development and commercialization of its drug candidates. The company's revenue model is based on securing funding and partnerships to advance its drug pipeline through clinical trials and towards market approval. Key revenue streams include research and development partnerships, grants, and potential licensing agreements with larger pharmaceutical companies. These collaborations help Appili to share the development costs and risks while providing access to broader distribution channels once the drugs are approved. Additionally, the company may earn milestone payments and royalties from successful commercialization of its therapeutics. Appili's focus on addressing unmet medical needs in infectious diseases positions it to attract interest from the healthcare industry and government agencies, further supporting its revenue generation efforts.

Appili Therapeutics Inc Class A Financial Statement Overview

Summary

Appili Therapeutics Inc Class A is facing substantial financial challenges, including consistent unprofitability, high leverage, and negative equity. Despite slight improvements in cash flow, the company's financial health is concerning, necessitating efforts to improve revenue generation and manage debt.

Income Statement

Appili Therapeutics Inc Class A has faced significant challenges in revenue generation, with a substantial decline of 87.86% in revenue from 2024 to 2025. The company has consistently reported negative net income and EBIT over the years, indicating persistent unprofitability. Gross profit margins remain at 100% due to revenue matching the cost, but the overall profitability is severely impacted by high operating losses.

Balance Sheet

The company exhibits high leverage with a negative stockholders' equity, resulting in an undefined debt-to-equity ratio. The equity ratio is also negative, reflecting more liabilities than assets. This financial instability poses significant risks to the company's sustainability and future operations.

Cash Flow

Appili has demonstrated some improvement in cash flow management with a positive operating cash flow in 2025. However, the free cash flow remains volatile, with a sharp negative trajectory in previous years. The operating cash flow to net income ratio is not favorable due to continuous negative net income, indicating challenges in converting revenue into cash.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	100.44K	827.41K	334.18K	1.39M	0.00
Gross Profit	100.44K	827.41K	327.91K	1.39M	-14.84K
EBITDA	360.57K	-2.10M	-8.19M	-24.31M	-14.87M
Net Income	-2.62M	-3.78M	-9.24M	-25.12M	-14.33M
Balance Sheet
Total Assets	3.03M	1.49M	3.13M	8.28M	18.32M
Cash, Cash Equivalents and Short-Term Investments	1.23M	94.49K	2.47M	6.66M	16.12M
Total Debt	12.29M	8.18M	7.67M	4.98M	1.03M
Total Liabilities	16.43M	12.42M	10.53M	11.55M	5.56M
Stockholders Equity	-13.40M	-10.92M	-7.40M	-3.27M	12.75M
Cash Flow
Free Cash Flow	866.46K	-2.49M	-10.10M	-19.08M	-11.46M
Operating Cash Flow	868.82K	-2.46M	-10.10M	-19.08M	-11.45M
Investing Cash Flow	-2.36K	-29.06K	-3.17K	5.06M	-4.99M
Financing Cash Flow	193.68K	122.05K	5.91M	9.56M	17.02M

Appili Therapeutics Inc Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.50 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:APLI.

Appili Therapeutics Inc Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.32B	5.45	-4.00%	3.31%	9.92%	-18.97%
APLI	47 Neutral	$1.82M	―	34.61%	―	-86.89%	30.77%
NMLSF	―	$1.92M	4.82		―	―	―
RKV	―	C$12.05M	―	-203.41%	―	―	―
MYNDF	―	$2.42M	―		―	―	―
MRVL	22 Underperform	C$11.39M	―	45.74%	―	―	―
AWKNF	―	$2.86M	―		―	―	―

Appili Therapeutics Inc Class A Corporate Events

Appili Therapeutics Strengthens Biodefense Partnerships and Advances Drug Development

Appili Therapeutics has reported its financial and operational results for the first quarter of fiscal year 2026, highlighting significant progress in its government and biodefense partnerships. The company submitted seven funding proposals to U.S. government agencies, potentially securing up to US$137 million to advance its infectious disease and biodefense projects. Appili’s acceptance into the U.S. Medical CBRN Defense Consortium strengthens its role in U.S. preparedness efforts, while ongoing projects like the ATI-1701 vaccine candidate and the re-launch of LIKMEZ® in the U.S. market underscore its strategic initiatives. These developments are expected to enhance Appili’s industry positioning and offer new opportunities for collaboration and funding.

Appili Therapeutics Demonstrates Efficacy of Tularemia Vaccine Candidate

Appili Therapeutics announced a peer-reviewed publication in the journal Vaccine demonstrating the efficacy of its biodefense vaccine candidate, ATI-1701, against tularemia. The study showed that ATI-1701 provides robust and durable protection against aerosolized Francisella tularensis exposure in animal models, reinforcing its potential as a leading candidate for tularemia prevention. This development supports continued collaboration with the U.S. Department of Defense, as there is currently no approved vaccine for tularemia in major global markets, highlighting ATI-1701’s potential market value.

Appili Therapeutics Advances Infectious Disease Solutions with LIKMEZ Re-launch and Vaccine Developments

Appili Therapeutics has re-launched LIKMEZ, the first FDA-approved liquid oral suspension of metronidazole, in the U.S., addressing a significant gap for patients who have difficulty swallowing tablets. The company is also progressing with its ATI-1701 vaccine candidate for tularemia, supported by U.S. Air Force funding, and ATI-1801 for cutaneous leishmaniasis, with positive Phase 3 data. These developments highlight Appili’s strategic focus on infectious disease solutions and potential market impact.

Appili Therapeutics Ends Agreement with Aditxt, Secures Loan Extensions

Appili Therapeutics announced the formal termination of its arrangement agreement with Aditxt Inc., effective May 30, 2025. As a result, Appili is entitled to a termination fee of USD $1,000,000 from Aditxt. Additionally, Appili has secured three-month extensions on loans from Long Zone Holdings Inc. and Bloom Burton & Co. Inc., with repayment due by August 31, 2025. This termination and financial adjustments may impact Appili’s operations and financial positioning, but the company continues to focus on its mission to combat infectious diseases.

Appili Therapeutics Faces Termination of Agreement with Aditxt

Appili Therapeutics announced that Aditxt, Inc. has issued a notice to terminate their arrangement agreement effective May 31, 2025. As a result, Appili is entitled to a termination fee of USD $1,000,000, which may impact the company’s financials and strategic positioning in the biopharmaceutical industry.